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The authors would like to thank the GFCH for their com-
mentary on the recommendations for cytogenomic testing
[1]. We are pleased to note that they are in agreement for the
majority of aspects of our recommendations and appreciate
where the GFCH have expanded or provided clariﬁcation to
our statements.
In particular we were pleased that the GFCH concur with
the authors of the importance and value of chromosome-
banding analysis in the diagnostic pathway of haematolo-
gical neoplasms as well as the complementary nature of
different testing strategies. We note that the GFCH has a few
concerns and these are addressed individually below.
In replying to their comments, it is important to restate
that the recommendation document is a consensus docu-
ment of working practices for cytogenomic testing in a
number of different European countries and describes the
minimum testing required, and that national policies should
be taken into consideration [2]. We acknowledge that more
extensive testing is undertaken in some countries particu-
larly relating to the number of metaphases analysed and the
pathological entities tested by chromosome-banding analy-
sis. The aim of the recommendations was to provide the
practical advice to help laboratories prioritise and rationalise
cytogenomic testing where health care resources are
restricted and where the extent of testing is limited by
testing reimbursement.
Choice of sample: We agree with this recommendation
and thank them for the extra clariﬁcation provided to our
statement regarding the use of peripheral blood samples for
chromosome-banding analysis in this section.
For cell culture of AML the authors agree that these
rearrangements can be detected in 24 h cultures. The authors
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state that a 48 h culture should be considered but this was
not intended to be a requirement. This observation referred
mainly to historic data of t(15;17) cases when FISH or RT-
PCR were not widely available.
Choromosome banding analysis: We agree that the full
ISCN 2016 deﬁnition of a clone includes the example cited
but this is also covered by the statement provided in
our paper.
We agree that ideally 20 metaphases would be analysed
regardless of the result, and indeed are aware that many
laboratories do systematically analyse this number. How-
ever, a minimum of ten metaphases are considered accep-
table when an abnormal clone is detected, unless there is
suspicion of clonal evolution (e.g., one metaphase with
additional abnormality) where a more extensive analysis
should be performed.
Recommended testing: We state that chromosome-
banding analysis is mandatory for ALL in Table 2 [2].
However, for information, we refer to the publication of the
International Berlin–Frankfurt–Münster study group on
recommendations for the detection of prognostically rele-
vant genetic abnormalities in childhood B-cell precursor
acute lymphoblastic leukaemia [3]. The vast majority of
laboratories undertake chromosome analysis of childhood
B-cell ALL but our experience through EQA has also
shown that some laboratories are only following this strat-
egy when cases require risk stratiﬁcation. Of note, for the
new childhood ALLTogether trial karyotyping is not man-
datory in all cases provided sufﬁcient extensive ﬁrst line
testing using FISH, PCR, and SNP-array is performed.
FISH in AML: Regarding NUP98 in AML, the authors
are in agreement with this approach. We recognise that the
text should have stated 17 months-18 years not 5 years.
Waldenström macrogobulinemia (WM): The authors
consider that cytogenomic testing, including chromosome
analysis, for recurrent abnormalities should be undertaken
as the detection of disease-speciﬁc recurrent abnormalities
can be beneﬁcial in a differential diagnosis case. Many
laboratories would not undertake routine chromosome
analysis for all WM cases although we recognise that
country-speciﬁc guidelines may recommend this.
High grade B-cell lymphomas: We are in concordance
with the overall choice of probes to be used for this dis-
ease entity and agree that as MYC breakpoints are located
across a large genomic region the choice of adequate
FISH probe(s) is paramount. It is therefore important that
laboratories understand the limitations of FISH probes
when they select which probes to use.
Concerning chromosome analysis, many laboratories do
not undertake routine chromosome analysis of high grade
B-cell lymphoma where FISH is the priority testing for
these cases. We agree that karyotyping is useful, however,
this is not always possible. In addition, when karyotyping is
performed, this is also often supplemented by FISH ana-
lysis. Many laboratories no longer undertake chromosome
analysis but instead perform FISH on FFPE sections to
detect the most signiﬁcant abnormalities.
Reporting time: We are aware that a large number of
examinations are requested, and that laboratories can ﬁnd it
difﬁcult to adhere to recommended turnaround times but it
is important that laboratories organise the work ﬂow so that
reporting times can be met. Concerning prioritisation of
testing, we recommend that this is assigned according to
clinical need as reporting results in follow-up samples can
also be urgent since targeted therapy is frequently used in a
relapse or emerging relapse setting.
In summary, the authors are grateful for the response by
the GFCH to our recommendations as this has enabled us to
clarify certain points and address a few omissions. In
addition, both the recommendations and the GFCH under-
line the importance of cytogenetics and a combined
approach to testing. Finally, the authors recognise that dif-
ferent countries will have different approaches to ensure
that full testing is addressed and adoption of these recom-
mendations, together with this clariﬁcation, will assist in
further harmonisation of genetic testing.
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